Don't Rush To Reorganize FDA, McClellan Says
Former commissioner says agency has to think about getting biggest bang for the buck when considering a reorganization to disease-focused teams.
You may also be interested in...
Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.
Commissioner Gottlieb says new centers would follow template of Oncology Center of Excellence.
Deputy Office of New Drugs director says IND evaluation and post-market surveillance could be part of restructuring effort along with changes to application review.